cometadata/datacite-titles-descriptions-related-identifiers huggingface dataset:
DOI: 10.21227/zx02-aa97
title: Corona Virus (COVID-19) Tweets Dataset

description: Tweets Counter: 3.8 Million plus (collecting since Feb 1, 2020)Each database (*.db) contain three columns.First column: date and time of the tweetSecond column: tweetThird column: sentiment score for the particular tweet within the range [-1,1] with -1 being the most negative, 0 being the neutral and +1 being the most positive sentiment.The tweets have been collected by the LSTM model deployed here at sentiment.live.To make it easy for the NLP researchers to get access to the sentiment analysis of each collected tweet, the sentiment score out of TextBlob [2] has been appended as the last column. New databases will be added to this dataset every week. Bookmark this page for further updates. [1] https://sentiment.live/ [2] https://textblob.readthedocs.io/en/dev/
DOI: 10.18716/nmrshiftdb2/76115
title: NMR data for 5-chloropyridin-2-amine
DOI: 10.5281/zenodo.3709013
title: Dataset related to article "Peripheral Blood Stem Cells versus Bone Marrow for T Cell-Replete Haploidentical Transplantation with Post-Transplant Cyclophosphamide in Hodgkin Lymphoma."

description: Haploidentical stem cell transplantation (haplo-SCT) with post-transplant cyclophosphamide (PT-Cy) represents a potential curative strategy for patients with Hodgkin lymphoma (HL) when a matched related or unrelated donor is not available. The role of graft source, either bone marrow (BM) or peripheral blood stem cells (PBSCs), in this setting has not been fully elucidated. We performed a retrospective study on 91 patients with HL to compare the outcome after BM (n = 53) or PBSC (n = 38) transplant. Eighty-nine patients engrafted with no difference between BM and PBSCs in terms of median time for neutrophil (20 versus 20 days, P = .405) and platelet (26 versus 26.5 days, P = .994) engraftment. With a median follow-up of 40.2 months, 100-day cumulative incidences of grades II to IV acute graft-versus host disease (GVHD) and grades II to IV acute GVHD were 24% and 4%, respectively. Graft source was not associated with a different risk of acute GVHD both by univariate and multivariate analyses. Consistently, 1-year cumulative incidence of chronic GVHD was 7% with no differences between the 2 graft types (P = .761). Two-year rates of overall survival (OS), progression-free survival (PFS), nonrelapse mortality, and GVHD/relapse-free survival (GRFS) were 67%, 58%, 20%, and 52%, respectively. By univariate analysis, pretransplant disease status was the main variable affecting all outcomes. By multivariate analysis, PBSCs resulted in a protective factor for OS (hazard ratio [HR], .29; P = .006), PFS (HR, .38; P = .001), and GRFS (HR, .44; P = .020). The other independent variables affecting the final outcome were pretransplant disease status and hematopoietic cell transplant-specific comorbidity index. In conclusion, when planning a haplo-SCT with PT-Cy for patients with poor-risk HL, graft type is an important variable to take into account when selecting the best available donor.
DOI: 10.5281/zenodo.3709012
title: Dataset related to article "Peripheral Blood Stem Cells versus Bone Marrow for T Cell-Replete Haploidentical Transplantation with Post-Transplant Cyclophosphamide in Hodgkin Lymphoma."

description: Haploidentical stem cell transplantation (haplo-SCT) with post-transplant cyclophosphamide (PT-Cy) represents a potential curative strategy for patients with Hodgkin lymphoma (HL) when a matched related or unrelated donor is not available. The role of graft source, either bone marrow (BM) or peripheral blood stem cells (PBSCs), in this setting has not been fully elucidated. We performed a retrospective study on 91 patients with HL to compare the outcome after BM (n = 53) or PBSC (n = 38) transplant. Eighty-nine patients engrafted with no difference between BM and PBSCs in terms of median time for neutrophil (20 versus 20 days, P = .405) and platelet (26 versus 26.5 days, P = .994) engraftment. With a median follow-up of 40.2 months, 100-day cumulative incidences of grades II to IV acute graft-versus host disease (GVHD) and grades II to IV acute GVHD were 24% and 4%, respectively. Graft source was not associated with a different risk of acute GVHD both by univariate and multivariate analyses. Consistently, 1-year cumulative incidence of chronic GVHD was 7% with no differences between the 2 graft types (P = .761). Two-year rates of overall survival (OS), progression-free survival (PFS), nonrelapse mortality, and GVHD/relapse-free survival (GRFS) were 67%, 58%, 20%, and 52%, respectively. By univariate analysis, pretransplant disease status was the main variable affecting all outcomes. By multivariate analysis, PBSCs resulted in a protective factor for OS (hazard ratio [HR], .29; P = .006), PFS (HR, .38; P = .001), and GRFS (HR, .44; P = .020). The other independent variables affecting the final outcome were pretransplant disease status and hematopoietic cell transplant-specific comorbidity index. In conclusion, when planning a haplo-SCT with PT-Cy for patients with poor-risk HL, graft type is an important variable to take into account when selecting the best available donor.
DOI: 10.18716/nmrshiftdb2/76120
title: NMR data for 1-bromo-4-chloro-2-methylbenzene
DOI: 10.18716/nmrshiftdb2/76121
title: NMR data for dimethylthallanyl nitrate
DOI: 10.5281/zenodo.3709039
title: Dataset related to article "Vessels Encapsulating Tumor Clusters (VETC) Is a Powerful Predictor of Aggressive Hepatocellular Carcinoma.

description: We investigated the clinical significance of a vascular growth pattern of hepatocellular carcinoma (HCC), the vessels that encapsulate tumor clusters (VETC), previously linked to HCC metastatic dissemination. VETC was assessed in a large multi-institutional cohort of 541 resected HCCs from Italy, Korea and Japan, and matched against a full spectrum of clinical and pathological variables. The VETC phenotype (defined as ≥ 55% tumor area by CD34 immunostaining) was easily reproducible and reliably detectable in whole sections and small-sized tissues of tissue microarray. VETC HCCs represented 18.9% of the whole series, the lowest proportion occurring in the cohort with smallest tumors (8.7%, Japanese series). VETC was significantly associated with several clinical and pathological features such as high alfa-fetoprotein (AFP) level, tumor size greater than 5 cm, poor differentiation, macrotrabecular pattern, less compact pattern, less inflammatory infiltrates, and frequent microvascular invasion. VETC was associated with early recurrence (hazard ratio [HR]: 1.52 [1.06-2.19], P = 0.023), disease-free survival (HR: 1.66 [1.21-2.27], P = 0.002), and overall survival (HR: 2.26 [1.37-3.72], P = 0.001) at multivariable analysis. VETC affected the survival in HCC patients stratified for etiology (hepatitis C virus/hepatitis B virus), vascular invasion, and specific molecular phenotypes (β-catenin/GS+). This distinct vascular pattern was enriched in the recently reported macrotrabecular massive HCC subtype, which was seen in 7.8% (42 of 541) of patients and associated with high AFP levels and poor differentiation. Conclusion: The VETC pattern was found to be easily detectable in a consistent fraction of HCC and a powerful pathological finding affecting survival. This study suggests that the heterogeneous pattern of angiogenesis is involved in HCC behavior.
DOI: 10.5281/zenodo.3709038
title: Dataset related to article "Vessels Encapsulating Tumor Clusters (VETC) Is a Powerful Predictor of Aggressive Hepatocellular Carcinoma.

description: We investigated the clinical significance of a vascular growth pattern of hepatocellular carcinoma (HCC), the vessels that encapsulate tumor clusters (VETC), previously linked to HCC metastatic dissemination. VETC was assessed in a large multi-institutional cohort of 541 resected HCCs from Italy, Korea and Japan, and matched against a full spectrum of clinical and pathological variables. The VETC phenotype (defined as ≥ 55% tumor area by CD34 immunostaining) was easily reproducible and reliably detectable in whole sections and small-sized tissues of tissue microarray. VETC HCCs represented 18.9% of the whole series, the lowest proportion occurring in the cohort with smallest tumors (8.7%, Japanese series). VETC was significantly associated with several clinical and pathological features such as high alfa-fetoprotein (AFP) level, tumor size greater than 5 cm, poor differentiation, macrotrabecular pattern, less compact pattern, less inflammatory infiltrates, and frequent microvascular invasion. VETC was associated with early recurrence (hazard ratio [HR]: 1.52 [1.06-2.19], P = 0.023), disease-free survival (HR: 1.66 [1.21-2.27], P = 0.002), and overall survival (HR: 2.26 [1.37-3.72], P = 0.001) at multivariable analysis. VETC affected the survival in HCC patients stratified for etiology (hepatitis C virus/hepatitis B virus), vascular invasion, and specific molecular phenotypes (β-catenin/GS+). This distinct vascular pattern was enriched in the recently reported macrotrabecular massive HCC subtype, which was seen in 7.8% (42 of 541) of patients and associated with high AFP levels and poor differentiation. Conclusion: The VETC pattern was found to be easily detectable in a consistent fraction of HCC and a powerful pathological finding affecting survival. This study suggests that the heterogeneous pattern of angiogenesis is involved in HCC behavior.
DOI: 10.18716/nmrshiftdb2/76123
title: NMR data for ethyl (Z)-2-fluoro-3-(4-nitrophenyl)prop-2-enoate
DOI: 10.5281/zenodo.3709016
title: Nanoscale Imaging of High-Field Magnetic Hysteresis in Meteoritic Metal Using X-Ray Holography

description: Data of magnetisation (two datasets) of the cloudy zone of Tazewell IIICD iron meteorite. Data was obtained using X-ray holography. Magnetization data is a 3D matrix containing magnetisation data in form of data[x location][y location][applied field], applied field values is provided in a separate file. Further details about this dataset and conditions of measurements can be found in Blukis et al., 2020 submitted to Geochemistry, Geophysics, Geosystems
DOI: 10.5281/zenodo.3709017
title: Nanoscale Imaging of High-Field Magnetic Hysteresis in Meteoritic Metal Using X-Ray Holography

description: Data of magnetisation (two datasets) of the cloudy zone of Tazewell IIICD iron meteorite. Data was obtained using X-ray holography. Magnetization data is a 3D matrix containing magnetisation data in form of data[x location][y location][applied field], applied field values is provided in a separate file. Further details about this dataset and conditions of measurements can be found in Blukis et al., 2020 submitted to Geochemistry, Geophysics, Geosystems
DOI: 10.18716/nmrshiftdb2/76131
title: NMR data for 2-(benzenesulfonyl)hex-1-en-3-one
DOI: 10.18716/nmrshiftdb2/76127
title: NMR data for [phenyl-(2,2,2-trifluoroacetyl)oxythallanyl] 2,2,2-trifluoroacetate
DOI: 10.5519/qd.5anea8ki
title: Query on the Natural History Museum Data Portal (data.nhm.ac.uk) (789802 records)
DOI: 10.18716/nmrshiftdb2/76117
title: NMR data for 6-chloropyridin-3-amine
DOI: 10.18716/nmrshiftdb2/76119
title: NMR data for 5-bromopyrimidine
DOI: 10.18716/nmrshiftdb2/76129
title: NMR data for InChI=1S/C13H16OS/c1-10-8-13(15(14)9-11(10)2)12-6-4-3-5-7-12/h3-7,13H,8-9H2,1-2H3
DOI: 10.18716/nmrshiftdb2/76122
title: NMR data for methyl 3-nitrobenzoate
DOI: 10.18716/nmrshiftdb2/76114
title: NMR data for 4-bromopyridine
DOI: 10.18716/nmrshiftdb2/76126
title: NMR data for InChI=1S/C9H7BrO3/c1-12-5-2-3-6-7(4-5)13-9(10)8(6)11/h2-4,9H,1H3
DOI: 10.18716/nmrshiftdb2/76130
title: NMR data for InChI=1S/C11H12OS/c12-13-9-5-4-8-11(13)10-6-2-1-3-7-10/h1-7,11H,8-9H2
DOI: 10.18716/nmrshiftdb2/76125
title: NMR data for InChI=1S/C7H13BrO3/c1-3-4-5-10-7(9)11-6(2)8/h6H,3-5H2,1-2H3
DOI: 10.18716/nmrshiftdb2/76128
title: NMR data for InChI=1S/C8H13NO3/c1-5(2)7-4-12-8(11)9(7)6(3)10/h5,7H,4H2,1-3H3
DOI: 10.18716/nmrshiftdb2/76134
title: NMR data for (3R,5R)-5-(iodomethyl)-2-methyl-3-phenyl-1,2-oxazolidine
DOI: 10.5281/zenodo.3707831
title: Partial dataset related to the article: "Fibrosis Rescue Improves Cardiac Function in Dystrophin-Deficient Mice and Duchenne Patient-Specific Cardiomyocytes by Immunoproteasome Modulation".

description: This record contains raw data related to the article: "Fibrosis Rescue Improves Cardiac Function in Dystrophin-Deficient Mice and Duchenne Patient-Specific Cardiomyocytes by Immunoproteasome Modulation". Abstract Patients affected by Duchenne muscular dystrophy (DMD) develop a progressive dilated cardiomyopathy<br> characterized by inflammatory cell infiltration, necrosis, and cardiac fibrosis. Standard<br> treatments consider the use of b-blockers and angiotensin-converting enzyme inhibitors that are<br> symptomatic and unspecific toward DMD disease. Medications that target DMD cardiac fibrosis are<br> in the early stages of development. We found immunoproteasome dysregulation in affected hearts<br> of mdx mice (murine animal model of DMD) and cardiomyocytes derived from induced pluripotent<br> stem cells of patients with DMD. Interestingly, immunoproteasome inhibition ameliorated cardiomyopathy<br> in mdx mice and reduced the development of cardiac fibrosis. Establishing the<br> immunoproteasome inhibitionedependent cardioprotective role suggests the possibility of modulating<br> the immunoproteasome as new and clinically relevant treatment to rescue dilated cardiomyopathy<br> in patients with DMD.
description: Supported by Italian Ministry of Health Conte Capitale 2015 (G.P.), Fondazione Umberto Veronesi (A.G.), and Fondazione IEO CCM (D.R.).
DOI: 10.5281/zenodo.3707832
title: Partial dataset related to the article: "Fibrosis Rescue Improves Cardiac Function in Dystrophin-Deficient Mice and Duchenne Patient-Specific Cardiomyocytes by Immunoproteasome Modulation".

description: This record contains raw data related to the article: "Fibrosis Rescue Improves Cardiac Function in Dystrophin-Deficient Mice and Duchenne Patient-Specific Cardiomyocytes by Immunoproteasome Modulation". Abstract Patients affected by Duchenne muscular dystrophy (DMD) develop a progressive dilated cardiomyopathy<br> characterized by inflammatory cell infiltration, necrosis, and cardiac fibrosis. Standard<br> treatments consider the use of b-blockers and angiotensin-converting enzyme inhibitors that are<br> symptomatic and unspecific toward DMD disease. Medications that target DMD cardiac fibrosis are<br> in the early stages of development. We found immunoproteasome dysregulation in affected hearts<br> of mdx mice (murine animal model of DMD) and cardiomyocytes derived from induced pluripotent<br> stem cells of patients with DMD. Interestingly, immunoproteasome inhibition ameliorated cardiomyopathy<br> in mdx mice and reduced the development of cardiac fibrosis. Establishing the<br> immunoproteasome inhibitionedependent cardioprotective role suggests the possibility of modulating<br> the immunoproteasome as new and clinically relevant treatment to rescue dilated cardiomyopathy<br> in patients with DMD.
description: Supported by Italian Ministry of Health Conte Capitale 2015 (G.P.), Fondazione Umberto Veronesi (A.G.), and Fondazione IEO CCM (D.R.).
DOI: 10.14469/hpc/6952
title: 2-isopropyl-5-methylphenyl 2-(p-tolyl)acetate

description: small amount of hexane impurity
DOI: 10.18716/nmrshiftdb2/76124
title: NMR data for (2R,3R)-2,3-diethyl-2-fluoro-3-iodooxirane
DOI: 10.5281/zenodo.3709116
title: Dataset related to article "Predicting survival and local control after radiochemotherapy in locally advanced head and neck cancer by means of computed tomography based radiomics."

description: PURPOSE: To appraise the ability of a radiomics signature to predict clinical outcome after definitive radiochemotherapy (RCT) of stage III-IV head and neck cancer. METHODS: A cohort of 110 patients was included in a retrospective analysis. Radiomics texture features were extracted from the gross tumor volumes contoured on planning computed tomography (CT) images. The cohort of patients was randomly divided into a training (70 patients) and a validation (40 patients) cohorts. Textural features were correlated to survival and control data to build predictive models. All the significant predictors of the univariate analysis were included in a multivariate model. The quality of the models was appraised by means of the concordance index (CI). RESULTS: A signature with 3 features was identified as predictive of overall survival (OS) with CI = 0.88 and 0.90 for the training and validation cohorts, respectively. A signature with 2 features was identified for progression-free survival (PFS; CI = 0.72 and 0.80); 2 features also characterized the signature for local control (LC; CI = 0.72 and 0.82). In all cases, the stratification in high- and low-risk groups for the training and validation cohorts led to significant differences in the actuarial curves. In the validation cohort the mean OS times (in months) were 78.9 ± 2.1 vs 67.4 ± 6.0 in the low- and high-risk groups, respectively, the PFS was 73.1 ± 3.7 and 50.7 ± 7.2, while the LC was 78.7 ± 2.1 and 63.9 ± 6.5. CONCLUSION: CT-based radiomic signatures that correlate with survival and control after RCT were identified and allow low- and high-risk groups of patients to be identified.
DOI: 10.5281/zenodo.3709117
title: Dataset related to article "Predicting survival and local control after radiochemotherapy in locally advanced head and neck cancer by means of computed tomography based radiomics."

description: PURPOSE: To appraise the ability of a radiomics signature to predict clinical outcome after definitive radiochemotherapy (RCT) of stage III-IV head and neck cancer. METHODS: A cohort of 110 patients was included in a retrospective analysis. Radiomics texture features were extracted from the gross tumor volumes contoured on planning computed tomography (CT) images. The cohort of patients was randomly divided into a training (70 patients) and a validation (40 patients) cohorts. Textural features were correlated to survival and control data to build predictive models. All the significant predictors of the univariate analysis were included in a multivariate model. The quality of the models was appraised by means of the concordance index (CI). RESULTS: A signature with 3 features was identified as predictive of overall survival (OS) with CI = 0.88 and 0.90 for the training and validation cohorts, respectively. A signature with 2 features was identified for progression-free survival (PFS; CI = 0.72 and 0.80); 2 features also characterized the signature for local control (LC; CI = 0.72 and 0.82). In all cases, the stratification in high- and low-risk groups for the training and validation cohorts led to significant differences in the actuarial curves. In the validation cohort the mean OS times (in months) were 78.9 ± 2.1 vs 67.4 ± 6.0 in the low- and high-risk groups, respectively, the PFS was 73.1 ± 3.7 and 50.7 ± 7.2, while the LC was 78.7 ± 2.1 and 63.9 ± 6.5. CONCLUSION: CT-based radiomic signatures that correlate with survival and control after RCT were identified and allow low- and high-risk groups of patients to be identified.
DOI: 10.14469/hpc/6950
title: 2-isopropyl-5-methylphenyl 2-(p-tolyl)acetate

description: small amount of hexane impurity
DOI: 10.14469/hpc/6951
title: 2-isopropyl-5-methylphenyl 2-(4-chlorophenyl)acetate

description: ethyl acetate impurity
DOI: 10.14457/cu.the.2006.256
title: ผลกระทบของกำไรสุทธิตามวิธีส่วนได้เสียและวิธีราคาทุน ที่มีต่อผลตอบแทนของหลักทรัพย์ /
DOI: 10.5281/zenodo.3709111
title: Dataset related to article "Predictive factors for progression of patients with carcinoma in situ of the bladder at long-term follow-up: pure versus non-pure CIS."

description: BACKGROUND: The aim of this study was to identify the predictive factors for progression defined as any event that shifted the management of the disease from a bladder sparing approach, by comparing patients with pure versus non-pure carcinoma in situ (CIS) of the bladder. METHODS: A retrospective analysis was carried out in consecutive patients affected by newly-diagnosed pure CIS and non-pure CIS (excluding cases with concomitant muscle invasive cancer). All patients were enrolled a in our institution from 1998 to 2010. Data was prospectively collected. Main end point was progression-free survival. RESULTS: Overall, 149 patients with CIS were identified for the analysis. A total of 98 patients had pure CIS (66%). Median follow-up was 103 months (range: 40-206 months). Progression occurred in 29 patients (19%). A total of 30 patients died during the follow-up (20%). In 13 cases (9%), the death was cancer specific. Progression-free survival estimate was 181 months (95% CI: 169-193 months) and 154 months (95% CI: 133-176 months) respectively for pure and non-pure CIS population (P=0.03). Among examined variables (age, gender, symptoms, smoking habit, ASA score, number of bacillus Calmette-Guérin [BCG] instillations), multivariate analysis disclosed that only CIS type was an independent predictor of progression (P=0.03) with a relative risk of 0.37 in favor of pure CIS. CONCLUSIONS: Pure and non-pure CIS are efficiently treated by BCG therapy combined with trans-urethral resection and/or radical cystectomy, with relatively low rate of progression. CIS type was the only significant predictor of progression.
DOI: 10.5281/zenodo.3709110
title: Dataset related to article "Predictive factors for progression of patients with carcinoma in situ of the bladder at long-term follow-up: pure versus non-pure CIS."

description: BACKGROUND: The aim of this study was to identify the predictive factors for progression defined as any event that shifted the management of the disease from a bladder sparing approach, by comparing patients with pure versus non-pure carcinoma in situ (CIS) of the bladder. METHODS: A retrospective analysis was carried out in consecutive patients affected by newly-diagnosed pure CIS and non-pure CIS (excluding cases with concomitant muscle invasive cancer). All patients were enrolled a in our institution from 1998 to 2010. Data was prospectively collected. Main end point was progression-free survival. RESULTS: Overall, 149 patients with CIS were identified for the analysis. A total of 98 patients had pure CIS (66%). Median follow-up was 103 months (range: 40-206 months). Progression occurred in 29 patients (19%). A total of 30 patients died during the follow-up (20%). In 13 cases (9%), the death was cancer specific. Progression-free survival estimate was 181 months (95% CI: 169-193 months) and 154 months (95% CI: 133-176 months) respectively for pure and non-pure CIS population (P=0.03). Among examined variables (age, gender, symptoms, smoking habit, ASA score, number of bacillus Calmette-Guérin [BCG] instillations), multivariate analysis disclosed that only CIS type was an independent predictor of progression (P=0.03) with a relative risk of 0.37 in favor of pure CIS. CONCLUSIONS: Pure and non-pure CIS are efficiently treated by BCG therapy combined with trans-urethral resection and/or radical cystectomy, with relatively low rate of progression. CIS type was the only significant predictor of progression.
DOI: 10.14457/cu.the.2006.519
title: การสร้างอัตลักษณ์ของคนมอญย้ายถิ่น : ศึกษากรณีแรงงานข้ามชาติในจังหวัดสมุทรสาคร /
DOI: 10.18716/nmrshiftdb2/76132
title: NMR data for InChI=1S/C11H14O4S/c1-9(12)11(8-15-2)16(13,14)10-6-4-3-5-7-10/h3-7,11H,8H2,1-2H3
DOI: 10.14469/hpc/6954
title: 4-allyl-2-methoxyphenyl heptadecanoate

description: White Crystals at RTP Melting Point: 46.7 degrees Celcius
DOI: 10.14469/hpc/6956
title: 2-methoxyphenyl-2-(4-methoxyphenyl)acetate

description: Possible guaiacol and 4-methoxyphenylacetic acid impurity
DOI: 10.14469/hpc/6955
title: 1-(2-isopropyl-5-methylphenoxy)-3-(p-tolyl)propan-2-one

description: A collection of data for our first year synthesis labs involving the synthesis of a novel ester. The ester synthesised being 1-(2-isopropyl-5-methylphenoxy)-3-(p-tolyl)propan-2-one. In the NMR data there is a hexane peak, indicating that the solvent had not fully dissolved.